Actively Recruiting

Age: 18Years +
All Genders
ID05383287

Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction (TRAITS-HFpEF)

Led by Manchester University NHS Foundation Trust · Updated on 2025-10-01

1250

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure where the heart does not pump blood properly, causing symptoms like breathlessness, tiredness, and swollen feet or ankles. The reasons why people develop HFpEF are not well understood, and current treatment options are limited. This observational study called TRAITS-HFpEF aims to better understand the causes of HFpEF, identify new tests and treatments, and gather information about the life expectancy of people living with this condition by collecting routine data from patients attending a specialized outpatient HFpEF clinic. The study involves recruiting approximately 1,250 patients who visit the HFpEF clinic at Manchester University NHS Foundation Trust over a 5-year period. With patient consent, a blood sample of about 10mL may be taken for biobanking to study potential new biomarkers, including plasma and DNA. All clinical information will be collected and documented at the time of recruitment to help identify different HFpEF patient types and their outcomes. Participants will be observed over approximately 7.5 years to monitor outcomes such as overall mortality and hospitalizations due to heart failure. Researchers will regularly collect clinical data and track patient health status during this time. The study will help characterize HFpEF patient groups and inform future research and specialist care strategies. Participation involves routine clinic visits and optional blood sample collection, with no study treatments administered.

CONDITIONS

Brief Title

Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction (TRAITS-HFpEF)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients attending the HFpEF clinic at Manchester University NHS Foundation Trust
Not Eligible

You will not qualify if you...

  • Age under 18 years
  • Imprisonment
  • Inability to provide full written or verbal informed consent in English

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Surveillance

Duration - Up to 7.5 years

Participants are observed over time to assess clinical variables and outcomes related to heart failure with preserved ejection fraction (HFpEF).

Participants attend a specialist HFpEF clinic for assessments and optional blood sample collection at recruitment.

Trial Site Locations

Total: 1 location

1

Manchester University NHS Foundation trust

Manchester, United Kingdom, M13 9WU

Actively Recruiting

Loading map...

Research Team

F

Fardad Soltani, MBChB, MRCP

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

Smart Monitoring and Analysis System Based on Artificial Int...

Chronic Heart Failure

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Piotr Ponikowski, Adriaan A Voors, Stefan D Anker...

https://pubmed.ncbi.nlm.nih.gov/27207191